文献速递免疫规划

一项随机、阳性对照、多中心II期临床研究:评估全液体DTwP-HepB-IPV-Hib六价疫苗(HEXASIIL®)在印度幼儿中的安全性和免疫原性

A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers.
PubMed 文献 · Vaccine · 2024-09-19

这项II期随机对照试验在印度12-24月龄健康幼儿中比较HEXASIIL®与Pentavac SD+Poliovac加强接种的安全性和免疫原性。222名受试者接种后,两组征集性不良事件发生率相当(85.5% vs 90.2%),多数为轻中度,均完全缓解。破伤风、Hib、脊灰1型和3型血清保护率两组均为100%。

要点

  • HEXASIIL®组与对照组征集性不良事件发生率相当(85.5% vs 90.2%),多为轻中度且完全缓解。
  • 接种后破伤风、Hib、脊灰1型和3型血清保护率两组均为100%。
  • 白喉血清保护率HEXASIIL®组99.1% vs 对照组100%,脊灰2型98.2% vs 100%。

核心结论

  • HEXASIIL®疫苗在幼儿中被发现安全且有免疫原性,并支持其在婴儿中进一步临床开发。

研究设计与样本

  • 这是一项在印度开展的II/III期、开放标签、多中心、对照试验,本稿报告II期结果。
  • 12-24月龄健康幼儿按1:1随机接受0.5 ml HEXASIIL®或对照疫苗Pentavac SD+Poliovac加强剂次肌肉注射。
  • 接种后随访28天评估安全性,接种前和接种后28天采集血样评估免疫原性。
  • 共223名受试者被随机分组,1名在接种前因撤回知情同意退出,222名受试者接种了研究疫苗(HEXASIIL®组110名,对照组112名)。
  • 安全性和免疫原性分析采用描述性汇总统计。

主要发现

  • HEXASIIL®组与对照组征集性不良事件频率相当(85.5% vs 90.2%)。
  • 大多数局部和全身征集性不良事件为轻中度,所有事件均完全缓解且无后遗症,无受试者因不良事件退出。
  • 未报告疫苗相关严重不良事件。
  • 接种后破伤风、Hib、脊灰1型和3型血清保护率两组均为100%。
  • 白喉血清保护率HEXASIIL®组99.1% vs 对照组100%,脊灰2型98.2% vs 100%;乙肝血清保护率两组均>99%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination vaccines are effective in simplifying complex vaccination schedules involving multiple vaccines. A fully liquid hexavalent diphtheria (D)-tetanus (T)-whole-cell pertussis (wP)- hepatitis B (HepB)-inactivated poliovirus (IPV)-Haemophilus influenzae b (Hib) vaccine (HEXASIIL®), manufactured by Serum Institute of India Pvt. Ltd. was tested for safety and immunogenicity following booster vaccination. METHODS: This was a phase-II/III, open label, multicentric, controlled trial in toddlers (phase II) and infants (phase III) in India. This manuscript presents results of phase II. Healthy toddlers aged 12-24 months were randomized (1:1) to receive a 0.5 ml booster dose of HEXASIIL® or comparator Pentavac SD + Poliovac, intramuscularly and followed for 28 days for safety assessment. Blood samples were collected pre-vaccination and 28 days post-vaccination to assess immunogenicity. Descriptive summary statistics were provided for safety and immunogenecity analyses. RESULTS: A total of 223 subjects were randomized. One subject droped out prior to dosing, due to consent withdrawal. Thus, 222 subjects received study vaccine (110 HEXASIIL® and 112 comparator). Frequency of solicited adverse events was comparable between HEXASIIL® and comparator (85.5 % vs 90.2 %). Most local and systemic solicited AEs were mild to moderate in severity. All events resolved completely without any sequelae and none led to subject discontinuation. No vaccine related serious AE was reported. Post vaccination, seroprotection rates against tetanus, Hib and polio type 1 and 3 were 100 % in both the groups. Seroprotection rates for diphtheria (99.1 % vs 100 %) and polio type 2 (98.2 % vs 100 %) were observed in HEXASIIL® and comparator group, respectively. For Hepatitis B, seroprotection was >99 % in both groups. Seroconversion observed for Bordetella Pertussis (94.5 % vs 95.4 %) and Pertussis Toxin (77.1 % vs 87.2 %) in HEXASIIL® and comparator group, respectively. CONCLUSION: HEXASIIL® vaccine was found to be safe and immunogenic in toddlers and supported its further clinical development in infants. Clinical Trial Registration - CTRI/2019/11/022052.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sharma H, Parekh S, Pujari P, et al. A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers. Vaccine. 2024. PMID: 39303376. doi:10.1016/j.vaccine.2024.126380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。